Lipid peroxidation in diabetes mellitus

Antioxidants and Redox Signaling

Volumn 7, Issue 1-2, 2005, Pages 256-268

  Davì, Giovanni ^a,c   Falco, Angela ^a   Patrono, Carlo ^b  

^a UNIVERSITY OF CHIETI   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

^c Center of Excellence on Aging   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ISOPROSTANE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANTIOXIDANT ACTIVITY; CONTROLLED STUDY; DIABETES MELLITUS; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN RELEASE; INSULIN RESISTANCE; LIPID PEROXIDATION; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; REVIEW; SIGNAL TRANSDUCTION; THROMBOCYTE ACTIVATION; VASCULAR DISEASE;

ANIMALS; ANTIOXIDANTS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIUM, VASCULAR; HUMANS; HYPERGLYCEMIA; INSULIN RESISTANCE; ISLETS OF LANGERHANS; ISOPROSTANES; LIPID PEROXIDATION; MODELS, BIOLOGICAL; OXIDANTS; OXIDATION-REDUCTION; OXIDATIVE STRESS; PLATELET ACTIVATION; REACTIVE OXYGEN SPECIES; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 13244258258     PISSN: 15230864     EISSN: None     Source Type: Journal    
DOI: 10.1089/ars.2005.7.256     Document Type: Review

References (103)

1. Aiello LP and Wong JS. Role of vascular endothelial growth factor in diabetic vascular complications. Kidney Int 58: 113-119, 2000.
2. American Diabetes Association. Aspirin therapy in diabetes. Diabetes Care 25: s78-s79, 2002.
3. Apfel SC. Neurotrophic factors and diabetic peripheral neuropathy. Eur Neurol 41: 27-34, 1999.
4. Bagi Z, Koller A, and Kaley G. PPARgamma activation, by reducing oxidative stress, increases NO bioavailability in coronary arterioles of mice with type 2 diabetes. Am J Physiol Heart Circ Physiol 286: H742-H748, 2004.
5. Bakker SJ, Ijzerman RG, Teerlink T, Westerhoff HV, Gans RO, and Heine RJ. Cytosolic triglycerides and oxidative stress in central obesity: the missing link between excessive atherosclerosis, endothelial dysfunction, and beta cell failure? Atherosclerosis 148: 17-21, 2000.
6. Baynes JW and Thorpe SR. Role of oxidative stress in diabetic complications: a new perspective on an old paradigm. Diabetes 48: 1-9, 1999.
7. Bayraktutan U. Free radicals, diabetes and endothelial dysfunction. Diabetes Obes Metab 4: 224-238, 2002.
8. Benjamin SM, Valdez R, Geiss LS, Rolka DB, and Narayan KM. Estimated number of adults with prediabetes in the U.S. in 2000: opportunities for prevention. Diabetes Care 26: 645-649, 2003.
9. Boyle JP, Honeycutt AA, Narayan KM, Hoerger TJ, Geiss LS, Chen H, and Thompson TJ. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care 24: 1936-1940, 2001.
10. Brodsky SV, Morrishow AM, Dharia N, Gross SS, and Goligorsky MS. Glucose scavenging of nitric oxide. Am J Physiol Renal Physiol 280: F480-F486, 2001.
11. Brownlee M. Negative consequences of glycation. Metabolism 49: 9-13, 2000.
12. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. Nature 414: 813-820, 2001.
13. Catella-Lawson F and FitzGerald GA. Oxidative stress and platelet activation in diabetes mellitus. Diabetes Res Clin Pract 30: 13-18, 1996.
14. Ceriello A. The possible role of postprandial hyperglycaemia in the pathogenesis of diabetic complications. Diabetologia 46: M9-M16, 2003.
15. Ceriello A. New insights on oxidative stress and diabetic complications may lead to a "causal" antioxidant therapy. Diabetes Care 26: 1589-1596, 2003.
16. Ceriello A, Bortolotti N, Falleti E, Taboga C, Tonutti L, Crescentini A, Motz E, Lizzio S, Russo A, and Bartoli E. Total radical-trapping antioxidant parameter in NIDDM patients. Diabetes Care 20: 194-197, 1997.
17. Ceriello A, Bortolotti N, Crescentini A, Motz E, Lizzio S, Russo A, Èzsol Z, Tonutti L, and Taboga C. Antioxidant defences are reduced during the oral glucose tolerance test in normal and non-insulin-dependent diabetic subjects. Eur J Clin Invest 28: 329-333, 1998.
18. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, and Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 25: 1439-1445, 2002.
19. Chisolm GM, Irwin KC, and Penn MS. Lipoprotein oxidation and lipoprotein-induced cell injury in diabetes. Diabetes 41: 61-66, 1992.
20. Cooke JP. The endothelium: a new target for therapy. Vasc Med 5: 49-53, 2000.
21. Cosentino F, Hishikawa K, Katusic ZS, and Luscher TF. High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circulation 96: 25-28, 1997.
22. Dandona P, Thusu K, Cook S, Snyder B, Makowski J, Armstrong D, and Nicotera T. Oxidative damage to DNA in diabetes mellitus. Lancet 347: 444-445, 1996.
23. Darko D, Dornhorst A, Kelly FJ, Ritter JM, and Chowienczyk PJ. Lack of effect of oral vitamin C on blood pressure, oxidative stress and endothelial function in type II diabetes. Clin Sci (Lond) 103: 339-344, 2002.
24. Davì G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, and Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 322: 1769-1774, 1990.
25. 2α is increased in hypercholesterolemia. Arterioscler Thromb Vasc Biol 17: 3230-3235, 1997.
26. Davì G, Gresele P, Violi F, Basili S, Catalano M, Giammarresi C, Volpato R, Nenci GG, Ciabattoni G, and Patrono C. Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. Circulation 96: 69-75, 1997.
27. 2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 99: 224-229, 1999.
28. Davì G, Di Minno G, Coppola A, Andria G, Cerbone AM, Madonna P, Tufano A, Falco A, Marchesani P, Ciabattoni G, and Patrono C. Oxidative stress and platelet activation in homozygous homocystinuria. Circulation 104: 1124-1128, 2001.
29. Davì G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, and Patrono C. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 288: 2008-2014, 2002.
30. Davì G, Chiarelli F, Santilli F, Pomilio M, Vigneri S, Falco A, Basili S, Ciabattoni G, and Patrono C. Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. Circulation 107: 3199-3203, 2003.
31. 2-isoprostane formation in hypercholesterolemic subjects. No further effect of vitamin E. Circulation 106: 2543-2549, 2002.
32. De Cristofaro R, Rocca B, Vitacolonna E, Falco A, Marchesani P, Ciabattoni G, Landolfi R, Patrono C, and Davì G. Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. J Thromb Haemost 1: 250-256, 2003.
33. Devaraj S, Hirany SV, Burk RF, and Jialal I. Divergence between LDL oxidative susceptibility and urinary F(2)-isoprostanes as measures of oxidative stress in type 2 diabetes. Clin Chem 47: 1974-1979, 2001.
34. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 82: 47-95, 2002.
35. Ellis EA, Grant MB, Murray FT, Wachowski MB, Guberski DL, Kubilis PS, and Lutty GA. Increased NADH oxidase activity in the retina of the BBZ/WOR diabetic rat. Free Radic Biol Med 24: 111-120, 1998.
36. Evans JL, Goldfine TD, Maddux BA, and Grodsky GD. Oxidative stress and stress-activated signaling pathways: a unifyng hypothesis of type 2 diabetes. Endocr Rev 23: 599-622, 2002.
37. Fairfield KM and Fletcher RH. Vitamins for chronic disease prevention in adults: scientific review. JAMA 287: 3116-3126, 2002.
38. Feldman EL. Oxidative stress and diabetic neuropathy: a new understanding of an old problem. J Clin Invest 111: 431-433, 2003.
39. Flyvbjerg A. Putative pathophysiological role of growth factors and cytokines in experimental diabetic kidney disease. Diabetologia 43: 1205-1223, 2000.
40. Fu MX, Wells-Knecht KJ, Blackledge JA, Lyons TJ, Thorpe SR, and Baynes JW. Glycation, glycoxidation, and cross-linking of collagen by glucose. Kinetics, mechanisms, and inhibition of late stages of the Maillard reaction. Diabetes 43: 676-683, 1994.
41. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 368: 225-229, 1995.
42. Gopaul NK, Manraj MD, Hebe A, Lee Kwai Van S, Johnston A, Carrier MJ, and Anggard EE. Oxidative stress could precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 44: 706-712, 2001.
43. Gotto AM. Lipid management in diabetic patients: lessons from prevention trials. Am J Med 112 Suppl 8A: 19S-26S, 2002.
44. Griendling KK, Sorescu D, and Ushio-Fukai M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res 86: 494-501, 2000.
45. Gutteridge JM and Halliwell B. Reoxygenation injury and antioxidant protection: a tale of two paradoxes. Arch Biochem Biophys 283: 223-226, 1990.
46. Haffner SM, Lehto S, Ronnemaa T, Pyorala K, and Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339: 229-234, 1998.
47. Hayden MR and Tyagi SC. Islet redox stress: the manifold toxicities of insulin resistance, metabolic syndrome and amylin derived islet amyloid in type 2 diabetes mellitus. JOP 3: 86-108, 2002.
48. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253-259, 2000.
49. Heart Protection Study Collaborative Group, MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 360: 23-33, 2002.
50. Hitsumoto T, Izuka T, Takahashi M, Yoshinaga K, Matsumoto J, Shimizu K, Kaku M, Sugiyama Y, Sakurai T, Aoyagi K, Kanai M, Noike H, Ohsawa H, Watanabe H, and Shirai K. Relationship between insulin resistance and oxidative stress in vivo. J Cardiol 42: 119-127, 2003.
51. Hoeldtke RD, Bryner KD, McNeill DR, Warehime SS, Van Dyke K, and Hobbs G. Oxidative stress and insulin requirements in patients with recent-onset type 1 diabetes. J Clin Endocrinol Metab 88: 1624-1628, 2003.
52. Kahn SE, Andrikopoulos S, and Verchere CB. Islet amyloid: a long-recognized but underappreciated pathological feature of type 2 diabetes. Diabetes 48: 241-253, 1999.
53. Kailasam MT, Parmer RJ, Tyrell EA, Henry RR, and O'Connor DT. Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk. J Hypertens 18: 1611-1620, 2000.
54. Keaney JF Jr and Loscalzo J. Diabetes, oxidative stress, and platelet activation. Circulation 99: 189-191, 1999.
55. Kelly DJ, Zhang Y, Hepper C, Gow RM, Javorski K, Kemp BE, Wilkinson-Berka JL, and Gilbert RE. Protein kinase C β inhibition attenuates the progression of experimental diabetic nephropathy in the presence of continued hypertension. Diabetes 52: 512-518, 2003.
56. Kritharides L and Stocker R. The use of antioxidant supplements in coronary heart disease. Atherosclerosis 164: 211-219, 2002.
57. Laakso M. Hyperglycemia and cardiovascular disease in type 2 diabetes. Diabetes 48: 937-942, 1999.
58. 2-isoprostanes evidence of oxidant stress in the insulin resistant, obese Zucker rat: effect of vitamin E. Eur J Pharmacol 377: 89-92, 1999.
59. Lee JH and McCarty R. Glycemic control of pain threshold in diabetic and control rats. Physiol Behav 47: 225-230, 1990.
60. Levine M, Wang Y, Padayatty SJ, and Morrow J. A new recommended dietary allowance of vitamin C for healthy young women. Proc Natl Acad Sci U S A 98: 9842-9846, 2001.
61. Lindemann S, Tolley ND, Dixon DA, McIntyre TM, Prescott SM, Zimmerman GA, and Weyrich AS. Activated platelets mediate inflammatory signaling by regulated interleukin 1β synthesis. J Cell Biol 154: 485-490, 2001.
62. Lonn E, Yusuf S, Hoogwerf B, Pogue J, Yi Q, Zinman B, Bosch J, Dagenais G, Mann JF, and Gerstein HC. Effects of vitamin E on cardiovascular and microvascular outcomes in high-risk patients with diabetes: results of the HOPE study and MICROHOPE substudy. Diabetes Care 25: 1919-1927, 2002.
63. Marchioli R, Schweiger C, Levantesi G, Tavazzi L, and Valagussa F. Antioxidant vitamins and prevention of cardiovascular disease: epidemiological and clinical trial data. Lipids 36: S53-S63, 2001.
64. Maritim AC, Sanders RA, and Watkins JB III. Diabetes, oxidative stress, and antioxidants: a review. J Biochem Mol Toxicol 17: 24-38, 2003.
65. Martin-Gallan P, Carrascosa A, Gussinye M, and Dominguez C. Biomarkers of diabetes-associated oxidative stress and antioxidant status in young diabetic patients with or without subclinical complications. Free Radic Biol Med 34: 1563-1574, 2003.
66. McPherson JD, Shilton BH, and Walton DJ. Role of fructose in glycation and cross-linking of proteins. Biochemistry 21: 1901-1907, 1998.
67. Meade EA, McIntyre TM, Zimmerman GA, and Prescott SM. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem 274: 8328-8334, 1999.
68. Meagher EA. Treatment of atherosclerosis in the new millennium: is there a role for vitamin E? Prev Cardiol 6: 85-90, 2003.
69. Mezzetti A, Cipollone F, and Cuccurullo F. Oxidative stress and cardiovascular complications in diabetes: isoprostanes as new markers on an old paradigm. Cardiovasc Res 47: 475-488, 2000.
70. Miller M. The epidemiology of triglyceride as coronary artery disease risk factor. Clin Cardiol 48: 241-253, 1999.
71. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, Kamitani S, Harada M, Ishikawa M, Kuwahara K, Ogawa E, Hamanaka I, Takahashi N, Kaneshige T, Teraoka H, Akamizu T, Azuma N, Yoshimasa Y, Yoshimasa T, Itoh H, Masuda I, Yasue H, and Nakao K. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension 32: 3-8, 1998.
72. Montero A, Munger KA, Khan RZ, Valdivielso JM, Morrow JD, Guasch A, Ziyadeh FN, and Badr KF. F(2)-isoprostanes mediate high glucose-induced TGF-β synthesis and glomerular proteinuria in experimental type I diabetes. Kidney Int 58: 1963-1972, 2002.
73. 2α, a potent agonist of the vascular thromboxane/endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 44: 155-163, 1992.
74. Moussavi N, Renier G, Roussin A, Mamputu JC, Buithieu J, and Serri O. Lack of concordance between plasma markers of cardiovascular risk and intima-media thickness in patients with type 2 diabetes. Diabetes Obes Metab 6: 69-77, 2004.
75. Mujumdar VS, Aru GM, and Tyagi SC. Induction of oxidative stress by homocyst(e)ine impairs endothelial function. J Cell Biochem 82: 491-500, 2001.
76. Munzel T and Keaney JF Jr. Are ACE inhibitors a "magic bullet" against oxidative stress? Circulation 104: 1571-1574, 2001.
77. 2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 271: 159-165, 1996.
78. Pasceri V, Willerson JT, and Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 102: 2165-2168, 2000.
79. 2α is not mediated by thromboxane receptor isoforms. J Biol Chem 271: 14916-14924, 1996.
80. Remuzzi A, Viberti GC, Ruggenenti P, Battaglia C, Pagni R, and Remuzzi G. Glomerular response to hyperglycemia in human diabetic nephropathy. Am J Physiol 259: 545-552, 1990.
81. Robins SJ. Cardiovascular disease with diabetes or the metabolic syndrome: should statins or fibrates be first line lipid therapy? Curr Opin Lipidol 14: 575-583, 2003.
82. Ruderman NB, Williamson JR, and Brownlee M. Glucose and diabetic vascular disease. FASEB J 6: 2905-2914, 1992.
83. Ruilope LM. Renoprotection and renin-angiotensin system blockade in diabetes mellitus. Am J Hypertens 10: 325-331, 1997.
84. Russell JW, Golovoy D, Vincent AM, Mahendru P, Olzmann JA, Mentzer A, and Feldman EL. High glucose-induced oxidative stress and mitochondrial dysfunction in neurons. FASEB J 16: 1738-1748, 2002.
85. Sacco M, Pellegrini F, Roncaglioni MC, Avanzini F, Tognoni G, and Nicolucci A. Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients. Diabetes Care 26: 3264-3272, 2003.
86. Sakuraba H, Mizukami H, Yagihashi N, Wada R, Hanyu C, and Yagihashi S. Reduced beta-cell mass and expression of oxidative stress-related DNA damage in the islet of Japanese type II diabetic patients. Diabetologia 45: 85-96, 2002.
87. 2 isoprostanes. Diabetes Care 25: 537-541, 2002.
88. Schmeichel AM, Schmelzer JD, and Low PA. Oxidative injury and apoptosis of dorsal root ganglion neurons in chronic experimental diabetic neuropathy. Diabetes 52: 165-171, 2003.
89. Shichiri M, Kishikawa H, Ohkubo Y, and Wake N. Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 23 Suppl 2: B21-B29, 2000.
90. Stevens MJ, Obrosova I, Pop-Busui R, Greene DA, and Feldman EL. Pathogenesis of diabetic neuropathy. In: Ellenberg and Rifkin's Diabetes Mellitus, edited by Porte D Jr, Sherwin RS, and Baron A. New York, NY: McGraw-Hill, 2002, pp. 747-770.
91. Takeuchi A, Throckmorton DC, Brogden AP, Yoshizawa N, Rasmussen H, and Kashgarian M. Periodic high extracellular glucose enhances production of collagens III and IV by mesangial cells. Am J Physiol 268: 13-19, 1995.
92. The Diabetes Control and Complication Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977-986, 1993.
93. The UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 352: 854-865, 1998.
94. Tsai EC, Hirsch IB, Brunzell JD, and Chait A. Reduced plasma peroxyl radical trapping capacity and increased susceptibility of LDL to oxidation in poorly controlled IDDM. Diabetes 43: 1010-1014, 1994.
95. Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH, Harrison DG, and Tsao PS. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 88: 1291-1298, 2001.
96. Vaughan CJ, Murphy MB, and Buckley BM. Stalins do more than just lower cholesterol. Lancet 348: 1079-1082, 1996.
97. Wassmann S, Laufs U, Muller K, Konkol C, Ahlbory K, Baumer AT, Linz W, Bohm M, and Nickenig G. Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 22: 300-305, 2002.
98. Williamson JR, Kilo C, and Ido Y. The role of cytosolic reductive stress in oxidant formation and diabetic complications. Diabetes Res Clin Pract 45: 81-82, 1999.
99. Wiseman MJ, Saunders AJ, Keen H, and Viberti GC. Effect of blood glucose control on increased glomerular filtration rate and kidney size in insulin-dependent diabetes. N Engl J Med 312: 617-621, 1985.
100. Wolff SP, Jiang ZY, and Hunt JV. Protein glycation and oxidative stress in diabetes mellitus and ageing. Free Radic Biol Med 10: 339-352, 1991.
101. Yan SD, Zhu H, Zhu A, Golabek A, Du H, Roher A, Yu J, Soto C, Schmidt AM, Stern D, and Kindy M. Receptor-dependent cell stress and amyloid accumulation in systemic amyloidosis. Nat Med 6: 643-651, 2000.
102. Zhang J, Johnston G, Stebler B, and Keller ET. Hydrogen peroxide activates NFkappaB and the interleukin-6 promoter through NFkappaB-inducing kinase. Antioxid Redox Signal 3: 493-504, 2001.
103. Zhao H, Kalivendi S, Zhang H, Joseph J, Nithipatikom K, Vasquez-Vivar J, and Kalyanaraman B. Superoxide generation by eNOS. The influence of cofactors. Proc Natl Acad Sci U S A 95: 9220-9225, 1998.